Dr Fleischmann is board certified in internal medicine and rheumatology and is a Master of the American College of Rheumatology. Dr Fleischmann graduated from Columbia College, New York City, NY and trained in rheumatology at Columbia Presbyterian Medical Center, New York City, NY. He is a clinical professor of medicine at the University of Texas Southwestern Medical Center, co-Medical Director of the Metroplex Clinical Research Center, and co-Director of the Division of Rheumatology at the Texas Health Presbyterian Hospital, Dallas, TX.

Dr Fleischmann has been involved in the development of virtually all medications approved for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus and osteoarthritis in the USA, and has presented globally on their development. In addition, he has published approximately 300 peer-reviewed manuscripts and presented approximately 500 abstracts at major rheumatology meetings. Dr Fleischmann is editor-in-chief of Rheumatology and Therapy, sits on the editorial boards of Annals of the Rheumatic Diseases, RMD Open and The Journal of Rheumatology, and was a past international editor for Rheumatology (Oxford). In addition, he has acted as peer reviewer for multiple journals including Arthritis & Rheumatology, Arthritis Care & Research, Annals of Internal Medicine, New England Journal of Medicine, The Lancet, The Lancet Rheumatology and Journal of the American Medical Association.